Shire submits application for FDA approval of Gaucher drug

09/1/2009 | American City Business Journals

Shire filed a new-drug application with the FDA for velaglucerase alfa, a treatment for patients with Type 1 Gaucher disease, ahead of schedule. The company expedited development of the drug amid a shortage of rival drug Cerezyme, caused by a viral contamination at Genzyme's manufacturing facility in Boston.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ